Pfizer to charge $130 for COVID-19 vaccination once government stops making them free: Report

Ryan King

October 22, 03:59 PM October 22, 04:00 PM

Arms soon won't be the only things getting a pinch from the Pfizer COVID-19 vaccine — wallets may, as well.

Pfizer is expected to charge patients between $110 and $130 per vaccine when the federal government stops footing the bill, but it will try to keep the out-of-pocket price at zero for patients who have health insurance, according to the company.

"We are confident that the U.S. price point of the COVID-19 vaccine reflects its overall cost-effectiveness and ensures the price will not be a barrier for access for patients," Pfizer executive Angela Lukin said, per Reuters.

LIST OF GOP GOVERNORS DISMISSING COVID-19 VACCINE MANDATES FOR SCHOOL ENTRY

At the moment, the United States pays about $30 per dose of the Pfizer-BioNTech Comirnaty vaccine. Officials have said the funding could dry up this fall ahead of the winter season, when cases have skyrocketed during the past two years of the pandemic.

This is partly because Congress has not approved additional pandemic spending, including the $15 billion requested by the White House.

When the funding dries up, the financial burden for the vaccine will fall on the shoulders of the broader U.S. healthcare system, similar to flu shots. Healthcare experts have contended that the COVID-19 vaccine is likely to become a seasonal shot similar to the one for the flu.

Pfizer reportedly expects shots to be distributed via primary healthcare providers by early 2023, depending on the longevity of the government supply.

The $110 to $130 price point is specific to patients 12 and older. So far, the company has not yet decided on a price point for its COVID-19 vaccine aimed at younger patients.

Both Moderna and Pfizer have recently begun rolling out their bivalent booster shots, which target the original strain of COVID-19, as well as the omicron variant and some of its subvariants.

At least 14.8 million U.S. residents have received the updated booster shot since it became available last month, per Reuters.

Feds press booster as winter season surge approaches

Jessica Dobrinsky

September 08, 11:00 PM September 08, 11:00 PM

New COVID-19 booster shots from Pfizer and BioNTech have cleared all regulatory hurdles in time for the expected wintertime surge of the virus.

The new vaccine aims particularly to protect against further more infection of omicron, which over the past 10 months has spread to develop into the dominant COVID-19 variant circulating all around the planet. Notably, the booster shot depends on mRNA technological innovation, which scientists just before the COVID-19 pandemic noticed as a promising epidemiological resource. The mRNA engineering, when doing work correctly, teaches human cells how to make a protein that will result in an immune reaction inside of a person’s entire body.

The Facilities for Illness Control and Prevention endorses that these aged 12 and older get the new boosters. To receive the shot, a human being should have done principal vaccinations two months out from obtaining the booster.

The company credits the vaccines, 1st developed through the Trump administration and pushed widely by the Biden White Dwelling, as lifesaving innovations that are free of charge of cost. According to the CDC, persons who have experienced a person or two boosters have a .024% prospect of getting hospitalized thanks to a COVID-19-linked illness. For individuals beneath 50, the rate is even lessen, at .014%.

Federal officers estimate that far more than 200 million individuals are eligible for the new increase. In accordance to Monica Gandhi, an infectious condition pro at the College of California, San Francisco, the booster shot is strongly encouraged for those who are immunocompromised or are 60 several years of age and more mature.

Nonetheless, the booster grew to become offered through an unprecedented regulatory bypass by health care officers. The vaccine received approval as a result of the emergency use authorization, reflecting the Foodstuff and Drug Administration’s and the CDC’s frantic attempts to stop the even further distribute of the virus and its variants. EUA acceptance permitted the vaccine companies to skip valued displays of essential statistical evidence as a result of scientific trials.

The selection for EUA acceptance will come as a result of substantial self esteem that new clinical data are needless. Pfizer and BioNTech have submitted preclinical info on the vaccine's efficacy to the Fda, which is not publicly out there. They assume to start off scientific trials following thirty day period.

A release from Pfizer announced that the info analyzing the two vaccine candidates’ safety, tolerability, and immunogenicity demonstrated optimistic success.

“Both vaccine candidates demonstrated a favorable security and tolerability profile comparable to the Pfizer-BioNTech COVID-19 Vaccine,” it said.

In a news meeting, Dr. Peter Marks, the head of the FDA's vaccine evaluate place of work, stated, “We really do not know for a truth but irrespective of whether we will get to that very same amount, but that is the aim below. And that is what we believe that the evidence that we’ve witnessed assists place to.”

Nonetheless, some vaccination warning indications have emerged.

The director of Mayo Clinic’s Vaccine Investigate Team, Dr. Gregory Poland, created "existence-altering" tinnitus, a ringing in one or each ears, soon after his next shot. Poland has even so ongoing to advocate vaccination.

Myocarditis, an irritation of the heart, has also impacted 1 in 1,800 vaccinated balanced males. As a result, in 2021, Swedish wellness officials declared they would pause the Moderna vaccination for some groups.